Xyphos Biosciences Inc.
Records under this name other than the patents Xyphos Biosciences Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
Showing 1 to 9 of 9 · Back to Xyphos Biosciences Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,700,729 | Modified bacteriocins and methods for their use Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,445,639 | Recombinant bacteriophage and methods for their use Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,673,553 | Recombinant bacteriophage and methods for their use Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,732,586 | Modified bacteriocins and methods for their use Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,206,971 | Modified bacteriocins and methods for their use Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,673,291 | Diffocin and methods of use thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,115,354 | Diffocins and methods of use thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,161,882 | Monocins and Methods of Use Formerly held In force · High confidence | In force | High confidence | |
| US 11,440,948 | Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on car-cells Formerly held In force · USPTO record | In force | USPTO record |